


# 19<sup>th</sup>

## Residential Course on Clinical Pharmacology of Antiretrovirals



**WEDNESDAY 17 JAN 2024**

2:00 PM - 6:00 PM

**THURSDAY 18 JAN 2024**

9:00 AM - 6:30 PM

**FRIDAY 19 JAN 2024**

9:00 AM - 1:50 PM

[www.fcarvturin.it](http://www.fcarvturin.it)

With the patronage of:



**SIMIT**

Società Italiana  
di Malattie Infettive  
e Tropicali

The event is accredited in **residential** and **online** form



## Organizing Secretariat and CME Provider



### CONTACT

Phone: **+39 011 0267950**

Fax: **+39 011 0267954**

E-mail: **[segreteria@hdcons.it](mailto:segreteria@hdcons.it)**

Web: **[www.hdcons.it](http://www.hdcons.it)**

# COURSE RATIONALE

The COVID-19 pandemic has placed infection research into the spotlight, highlighting once again the complexity and devastating impact that infectious diseases can have. In the new world where communicable diseases are taking center stage, having solid infectious disease pharmacology knowledge is essential for patient care.

This course is a remarkable platform for learning, networking, and advancing our understanding of clinical pharmacology in the context of HIV, hepatitis, COVID-19, and other bacterial and fungal infections.

Bringing together experts from different fields, the course features interactive sessions and lively debate, all offering ample opportunities for engaging discussions and knowledge exchange.

Not only designed for clinicians involved in HIV management who wish to deepen their knowledge about PK/PD aspects of HIV research and medicine, the 3-day course is also a focus on novel issues covering proper use of MoAb and patient's prophylaxis, prescribing and monitoring procedures for a variety of drug regimens used to treat infectious diseases. Each topic focuses on preclinical, translational and clinical aspects and will be a valuable experience for all involved in infectious diseases, as researchers or prescribers of anti-infective agents.

## COURSE DIRECTOR

**G. Di Perri**

## SCIENTIFIC SECRETARIAT

**S. Bonora, A. Calcagno**

Phone: + 39 011 4393980/4393867, Fax: +39 011 4393882

E-mail: [stefano.bonora@unito.it](mailto:stefano.bonora@unito.it) - [andrea.calcagno@unito.it](mailto:andrea.calcagno@unito.it)



# FACULTY

**M. Andreoni**, Department of Infectious Diseases, University “Tor Vergata”, Rome, Italy.

**M. Bartoletti**, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Infectious Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

**M. Boffito**, Department of Sexual Health & HIV, Chelsea & Westminster NHS Trust, London, UK.

**S. Bonora**, Department of Infectious Diseases, University of Turin, Italy.

**M.R. Brunetto**, Gastroenterology Unit, Hospital and University of Pisa, Italy.

**A. Calcagno**, Department of Infectious Diseases, University of Turin, Italy.

**A. Castagna**, Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Italy.

**D. Cattaneo**, Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

**A. Ciancio**, Division of Gastroenterology and Hepatology, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.

**S. Corcione**, Department of Infectious Diseases, University of Turin, Italy.

**D. Corti**, Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

**J. Cusato**, Department of Infectious Diseases, University of Turin, Italy.

**A. D'Avolio**, Department of Infectious Diseases, University of Turin, Italy.

**F.G. De Rosa**, Department of Infectious Diseases, University of Turin, Italy.

**G. Di Perri**, Department of Infectious Diseases, University of Turin, Italy.

**M. Emerson**, Platelet Biology Group, Molecular Medi, National Heart and Lung Institute, Imperial College London, London, UK.

**M. Ferrara**, Department of Infectious Diseases, University of Turin, Italy.

**C.V. Fletcher**, Departments of Pharmacy Practice and Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, USA.

**M. Galli**, Department of Infectious Diseases, University of Milan, Italy.

**R. Garraffo**, Pharmacology Laboratory, CHU Pasteur, Nice, France.



**V. Chisetti**, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.

**S. Gianella Weibel**, Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA.

**A. Gori**, Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

**S. Khoo**, Department of Pharmacology and Therapeutics, University of Liverpool, UK.

**L. Kondili**, Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.

**P. Lampertico**, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Italy.

**S. Letendre**, Department of Infectious Diseases, University of California San Diego School of Medicine, La Jolla, CA, USA.

**G. Madeddu**, Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari.

**C. Marzolini**, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

**J. Moltò**, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.

**C. Mussini**, Institute of Infectious Diseases, University of Modena, Italy.

**E. Nicastri**, Department of Infectious Diseases, IRCCS "Lazzaro Spallanzani", Rome, Italy.

**G. Nunnari**, Institute of Infectious Diseases, University of Messina, Italy.

**A. Owen**, Department of Pharmacology and Therapeutics, Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.

**C.F. Perno**, Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy.

**M. Troisi**, Monoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.

**M. Trunfio**, Department of Infectious Diseases, University of Turin, Italy.

**P. Viale**, Infectious Diseases Unit, Department of Medical and Surgical Sciences, Policlinico Sant'Orsola Malpighi, University of Bologna.

## LANGUAGE

The official language of the Course is English.

There is no simultaneous interpretation.

Updated information will be found on the course website:  
[www.fcavrturin.it](http://www.fcavrturin.it)

# PROGRAMME

WEDNESDAY, **17 JAN 2024**  
AFTERNOON SESSION

**1<sup>st</sup>** WEBINAR

14:00 Course registration

14:40 Welcome and introduction to the Course (**G. Di Perri, S. Bonora, A. Calcagno**)

### SESSION I: COVID (Chair: **G. Di Perri, G. Madeddu**)

15:00 Complicated COVID: who is at risk in 2024? (**E. Nicastri**)

15:20 Combination therapies for COVID-19 in high-risk subjects (**S. Bonora**)

15:40 The pipeline of anti SARS-Cov-2 agents (**S. Khoo**)

16:00 Plenary discussion

16:30 *Coffee break*

### SESSION II: MONOCLONAL ANTIBODIES FOR INFECTIOUS DISEASE (Chair: **S. Bonora, A. Calcagno**)

16:50 Monoclonal antibodies for resistant bacteria (**M. Troisi**)

17:10 Clinical Pharmacology of Monoclonal Antibodies for COVID (**G. Di Perri**)

17:30 Plenary discussion

18:00 Closing remarks day 1



# THURSDAY, 18 JAN 2024

## MORNING SESSION



### SESSION III: TDM: MEASURING THE DRUGS TO MANAGE THE PATIENT (Chair: A. D'Avolio, R. Garraffo)

- 9:00 Is it worth to measure anti-HIV drugs in 2024? (**M. Ferrara**)
- 9:20 Pharmacogenomics of anti-infectives: what does tell the clinicians? (**J. Cusato**)
- 9:40 Antimicrobial TDM in critically ill adult patients (**M. Bartoletti**)
- 10:00 TDM of long-acting antibiotics in the clinical setting (**D. Cattaneo**)
- 10:20 Plenary discussion
- 10:50 *Coffee break*

### SESSION IV: CLINICAL PHARMACOLOGY AT THE BEDSIDE (Chair: A. Calcagno, A. Gori)

- 11:10 Keynote lecture: Polypharmacy and multiple DDIs in viral infections (**C. Marzolini**)
- 11:40 Keynote lecture: Management of DDI between Antiplatelet/DOAC and antivirals (**M. Emerson**)
- 12:10 Dosage of rifampicin and other antimycobacterial drugs: "The Times They Are a Changin'" (**A. Calcagno**)
- 12:30 Pharmacokinetic issues in the choice of newer antimicrobial agents (**F.G. De Rosa**)
- 12:50 Pharmacomicrobiomics of antinfective agents (**S. Corcione**)
- 13:10 Plenary discussion
- 13:30 *Lunch*



# THURSDAY, 18 JAN 2024

## AFTERNOON SESSION



### SESSION V: VIRAL HEPATITIS (Chair: A. Ciancio, L. Kondili)

- 14:30 Clinical Pharmacology of Bulevirtide (**G. Di Perri**)
- 14:50 Update on Hepatitis Delta treatment with Bulevirtide (**P. Lampertico**)
- 15:10 Current issue and long-term perspective in the treatment of HBV infection (**M.R. Brunetto**)
- 15:30 Plenary discussion
- 15:50 *Coffee break*

### SESSION VI: LONG ACTING AND EXTENDED DELIVERY REGIMENS (Chair: M. Andreoni, M. Galli)

- 16:10 Keynote lecture: New and Upcoming Long-Acting agents for HIV (**M. Boffito**)
- 16:40 Selection and management of patients treated with Long-Acting anti-HIV Agents (**A. Castagna**)
- 17:00 Pharmacokinetics of Long-Acting anti-HIV agents in the clinical setting (**M. Ferrara**)
- 17:20 Long-acting agents in antibacterial and antifungal treatments (**P. Viale**)
- 17:40 Innovative drug delivery systems for treatment and prophylaxis of infectious disease (**A. Owen**)
- 18:00 Plenary discussion
- 18:30 Closing remarks day 2





# FRIDAY, 19 JAN 2024

## MORNING SESSION



- 9:00 Introducing a Special Guest Speaker (**G. Di Perri, S. Bonora**)  
Design and development of Monoclonal Antibodies for infectious diseases  
(**D. Corti**)

### **SESSION VII: PLWH WITH LONG TERM THERAPEUTIC SUCCESS: A QUIET BUT COMPLEX WORLD (Chair: C. Mussini, C.F. Perno)**

- 9:30 HIV therapy optimization, beyond undetectability (**S. Bonora**)
- 9:50 2-drug oral regimens: long term data and clinical pharmacology  
(**G. Di Perri**)
- 10:10 DDIs in PWLH with cancer (**J. Moltò**)
- 10:30 CNS effects of HAART in 2024 (**A. Calcagno**)
- 10:50 Plenary discussion
- 11:10 *Coffee break*

### **SESSION VIII: CHALLENGING THE HIV RESERVOIR (Chair: G. Nunnari, V. Ghisetti)**

- 11:30 Keynote lecture: The long-term neurocognitive decline in PLWH: which lessons learned (**S. Letendre**)
- 12:00 Keynote lecture: A new viewpoint on deep tissue HIV reservoirs from the Last Gift Program (**S. Gianella Weibel**)
- 12:30 Tissue pharmacology of antiretrovirals: which role for HIV treatment and cure? (**C. Fletcher**)
- 12:50 Opioids and HIV reservoir: an unexpected relationship (**M. Trunfio**)
- 13:10 Plenary discussion
- 13:30 Closing remarks day 3 and CME questionnaire
- 13:50 *Buffet lunch*

## TARGET AUDIENCE

The course is designed for healthcare professionals who are actively involved in the medical care of people with HIV, HBV and HCV infection.

CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: Physicians, Hospital Pharmacists, Biologists, Chemists and Lab Technicians.

# CME Webinar

1

**WEDNESDAY, 17 JAN 2024**

**h. 2:00 PM - 6:00 PM**

CME Code: **546-401992**

Accredited with **4,5 CME credits** upon completion of the questionnaire after attending the live webinar

2

**THURSDAY, 18 JAN 2024**

**h. 9:00 AM - 1:30 PM**

CME Code: **546-402105**

Accredited with **6 CME credits** upon completion of the questionnaire after attending the live webinar

3

**THURSDAY, 18 JAN 2024**

**h. 2:30 PM - 6:30 PM**

CME Code: **546-402106**

Accredited with **4,5 CME credits** upon completion of the questionnaire after attending the live webinar

4

**FRIDAY, 19 JAN 2024**

**h. 9:00 AM - 1:50 PM**

CME Code: **546-402107**

Accredited with **4,5 CME credits** upon completion of the questionnaire after attending the live webinar

## HOW TO ATTEND THE WEBINARS

The day before the start of the Conference, an email will be sent to subscribers containing links and access credentials valid for all 4 modules.

The CME test must be completed within three days after the course has finished. At the end of the course it will be possible to download the certificate of participation directly from the online platform.

CME Code: **546-401972**

This congress is accredited with **14 CME credits** credits upon completion of the questionnaire after having attended all 3 days conference

## REGISTRATION

Registration available on [www.fcarvturin.it](http://www.fcarvturin.it)

**Registration is mandatory in order to attend the residential course**

Onsite registration includes:

- Admission to all course sessions
- Name tag
- Satchel
- Block notes and pen
- Free onsite wireless
- Coffee breaks and lunches indicated in the program
- Social Dinner

*Social Dinner is free of charge for participants, but is essential to confirm your presence.*

*In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intolerance or allergies.*

## RESIDENTIAL COURSE LOCATION

All sessions will be held at the

**Starhotels Majestic**

Corso Vittorio Emanuele II 54, Turin

Phone: +39 011 539153

Fax: +39 011 534963



# SPONSOR

*With the non-conditioning contribution of:*

## DIAMOND SPONSORS



## SILVER SPONSORS

**Johnson & Johnson**



[www.fcarvturin.it](http://www.fcarvturin.it)

SAVE **29**  
THE **31<sup>30</sup>**  
DATE **31<sup>30</sup>**  
**JANUARY**  
**2025**

## 20<sup>th</sup> Residential Course on Clinical Pharmacology of Antiretrovirals



## Organizing Secretariat and CME Provider



### CONTACT

Phone: **+39 011 0267950**

E-mail: **segreteria@hdcons.it** Web: **www.hdcons.it**